Thymosin Alpha-1
Immunomodulating peptide studied across immune dysfunction, chronic infections, and oncology support — approved in 35+ countries
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally secreted by the thymus gland. First isolated by Allan Goldstein in the 1970s, it is one of the best-characterized immunomodulatory peptides in clinical use, approved under the brand name Zadaxin in more than 35 countries for hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
Tα1 acts primarily by activating dendritic cells and T-lymphocytes through Toll-like receptor signaling, upregulating MHC class II antigen presentation, and promoting the shift toward a Th1 immune response. This makes it particularly effective in conditions where immune function is suppressed or dysregulated — including chronic viral infections, post-COVID immune dysfunction, and immune-compromised cancer patients undergoing chemotherapy.
Unlike immunosuppressants, Tα1 normalizes immune function rather than suppressing it, and its safety profile across decades of clinical use is excellent. It is one of the few peptides in this database with high-quality randomized controlled trial data supporting its use.
Primary Benefits
Synthetic peptide derived from human gastric juice, known for accelerating tissue repair and reducing inflammation
Alpha-MSH derived tripeptide with potent anti-inflammatory and gut healing properties, oral or subcutaneous
Human cathelicidin antimicrobial peptide — the body's primary endogenous antibiotic, with wound healing and immune defense roles